Tag Archives: AdComms

Drug Approvals and FDA AdComms in 2023

Having passed the mid-year point, it is always an interesting exercise to take stock of where we stand with respect to the approval of new medicines. Overall, when considering the volume of activity, things would seem to be looking up … Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Tagged , , , | Comments Off on Drug Approvals and FDA AdComms in 2023

Big Decisions – Reviewing FDA Advisory Committee Outcomes Since 2020

In January we took a look at FDA Advisory Committees (AdComms) – FDA AdComms – When the Going Gets Tough – noting, among other things that there had not only been fewer meetings but also that it appeared that the … Continue reading

Posted in Advisory Committee Prepapartion | Tagged , , , , | Comments Off on Big Decisions – Reviewing FDA Advisory Committee Outcomes Since 2020

Emerging from Emergency – Two COVID-Related Developments This Week

Two announcements occurred this week, both of note and connected only by the fact that they are emblematic of the slow metamorphosis from a COVID emergency world to a post-COVID emergency one. Emergency Ends – First, the Biden Administration announced … Continue reading

Posted in FDA Image, FDA Policy | Tagged , , , , | Comments Off on Emerging from Emergency – Two COVID-Related Developments This Week

AdComm Drop-off in 2019 – FDA Consults Fewer Experts in 2019

The system of FDA Advisory Committees is in place so that when FDA needs advice – either on policy development, reviewing an issue with an already approved medicine, or regarding new drug approvals – the agency has a lot of … Continue reading

Posted in Uncategorized | Tagged , , , | Comments Off on AdComm Drop-off in 2019 – FDA Consults Fewer Experts in 2019

Sorting it Out – FDA AdComm Review for 2018

In 2017, the Advisory Committees voted to recommend approval 71.4 percent of the time; in 2018 it was 66.6 percent. Continue reading

Posted in Advisory Committee Prepapartion | Tagged , , , | 1 Comment